Singapore markets open in 7 hours 54 minutes

Sino Biopharmaceutical Limited (1177.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
4.910+0.030 (+0.61%)
At close: 04:08PM HKT

Sino Biopharmaceutical Limited

Office Tower
Unit 09, 41st Floor, Room 4109 Convention Plaza 1 Harbour Road
Wan Chai
Hong Kong
852 2802 9886

Full-time employees25,552

Key executives

NameTitlePayExercisedYear born
Ms. Y. Y. TseExec. Chairwoman of the Board5.18MN/A1992
Mr. Eric S. Y. TseCEO & Exec. Director3.4MN/A1996
Mr. Ping TseFounder & Sr. Vice Chairman6.18MN/A1952
Ms. Cheung Ling ChengExec. Vice Chairwoman of the Board4.36MN/A1964
Ms. Mingqin LiVP & Exec. Director176.87kN/A1959
Mr. Zhoushan TianExec. Director267.37kN/A1964
Mr. Hsin TseVP & Exec. Director859.75kN/A1970
Ms. Chau Ling YuAssistant VP & Financial ControllerN/AN/A1969
Mr. Oi Nin ChanCompany Sec.N/AN/A1968
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Corporate governance

Sino Biopharmaceutical Limited’s ISS governance QualityScore as of 28 January 2023 is 7. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.